BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 32424201)

  • 1. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.
    Morimoto S; Ichihara A
    Hypertens Res; 2020 Aug; 43(8):744-753. PubMed ID: 32424201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.
    Shibata H; Itoh H
    Am J Hypertens; 2012 May; 25(5):514-23. PubMed ID: 22258336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy.
    Haase M; Riester A; Kröpil P; Hahner S; Degenhart C; Willenberg HS; Reincke M
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4397-402. PubMed ID: 25222758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.
    Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
    JAMA Cardiol; 2018 Aug; 3(8):768-774. PubMed ID: 30027227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism.
    Satoh M; Maruhashi T; Yoshida Y; Shibata H
    Hypertens Res; 2019 Jun; 42(6):817-824. PubMed ID: 30948836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent progress in the diagnosis and treatment of primary aldosteronism.
    Yoshida Y; Shibata H
    Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Primary aldosteronism: from diagnosis to therapy in clinical practice].
    Vetri M; Cassaniti L; Francese GM; Gulizia MM
    G Ital Cardiol (Rome); 2021 Apr; 22(4):319-326. PubMed ID: 33783452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary aldosteronism: Treatment of the disease, and new therapeutic approaches.
    Funder J
    Best Pract Res Clin Endocrinol Metab; 2020 Mar; 34(2):101368. PubMed ID: 31813785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Aldosteronism: Practical Approach to Diagnosis and Management.
    Byrd JB; Turcu AF; Auchus RJ
    Circulation; 2018 Aug; 138(8):823-835. PubMed ID: 30359120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
    Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
    Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
    Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
    Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Lales G; Mitas C; Doumas M
    Curr Pharm Des; 2018; 24(46):5508-5516. PubMed ID: 30854950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.
    Yoneda T; Demura M; Takata H; Kometani M; Karashima S; Yamagishi M; Takeda Y
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1109-13. PubMed ID: 22337911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited.
    Williams TA; Reincke M
    Eur J Endocrinol; 2018 Jul; 179(1):R19-R29. PubMed ID: 29674485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism.
    Wachtel H; Fraker DL
    Curr Cardiol Rep; 2021 Jun; 23(7):89. PubMed ID: 34081226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary aldosteronism: diagnostic and treatment strategies.
    Mattsson C; Young WF
    Nat Clin Pract Nephrol; 2006 Apr; 2(4):198-208; quiz, 1 p following 230. PubMed ID: 16932426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery?
    Sechi LA; Colussi GL; Novello M; Uzzau A; Catena C
    Horm Metab Res; 2015 Dec; 47(13):1000-6. PubMed ID: 26667803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of successful outcome in patients with primary aldosteronism.
    Moo TA; Zarnegar R; Duh QY
    Curr Treat Options Oncol; 2007 Aug; 8(4):314-21. PubMed ID: 18058076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.